当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

Abstract：

:Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there is no cure for MM, patients eventually become resistant to therapies, leading to development of relapsed/refractory MM. Therefore, an unmet need exists for MM treatments with novel mechanisms of action that can provide durable responses, evade resistance to prior therapies, and/or are better tolerated. B-cell maturation antigen (BCMA) is preferentially expressed by mature B lymphocytes, and its overexpression and activation are associated with MM in preclinical models and humans, supporting its potential utility as a therapeutic target for MM. Moreover, the use of BCMA as a biomarker for MM is supported by its prognostic value, correlation with clinical status, and its ability to be used in traditionally difficult-to-monitor patient populations. Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody-drug conjugates, and chimeric antigen receptor (CAR)-modified T-cell therapy. We provide an overview of preliminary clinical data from trials using these therapies, including the BiTE® (bispecific T-cell engager) immuno-oncology therapy AMG 420, the antibody-drug conjugate GSK2857916, and several CAR T-cell therapeutic agents including bb2121, NIH CAR-BCMA, and LCAR-B38M. Notable antimyeloma activity and high minimal residual disease negativity rates have been observed with several of these treatments. These clinical data outline the potential for BCMA-targeted therapies to improve the treatment landscape for MM. Importantly, clinical results to date suggest that these therapies may hold promise for deep and durable responses and support further investigation in earlier lines of treatment, including newly diagnosed MM.

journal_name

Leukemia

journal_title

Leukemia

authors

Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

doi

10.1038/s41375-020-0734-z

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

985-1005

issue

4

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-020-0734-z

journal_volume

34

pub_type

杂志文章,评审

相关文献

LEUKEMIA文献大全
  • Cancer increases risk of in-hospital death from COVID-19 in persons

    abstract：:The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0986-7

    authors： Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

    更新日期：2020-09-01 00:00:00

  • A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.

    abstract：:Chromosomal breakpoints associated with malignancy are known to cluster at particular regions of the karyotype. Based on a review of the literature we have identified a novel leukaemia syndrome associated with translocations involving 8p11. This syndrome is distinct from the previously described translocation t(8;16)(...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Macdonald D,Aguiar RC,Mason PJ,Goldman JM,Cross NC

    更新日期：1995-10-01 00:00:00

  • Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia.

    abstract：:The t(9;22)(q34;q11), generating the Philadelphia chromosome (Ph), is found in more than 90% of patients with chronic myeloid leukemia (CML) and in 15-30% of adults with acute lymphoblastic leukemia (ALL). Different groups have recently described the presence of large genomic deletions adjacent to the translocation br...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402829

    authors： Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Mancini M,Cuneo A,Pane F,Foà R,Manolelli F,Liso V,Rocchi M

    更新日期：2003-03-01 00:00:00

  • Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

    abstract：:Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0416-x

    authors： Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

    更新日期：2019-09-01 00:00:00

  • The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ('Ponte di legno meeting') report: Vienna, Austria, April 27-28, 2005.

    abstract：:The International Acute Lymphoblastic Leukemia Working Group, the so-called 'Ponte di Legno Workshop' has led to substantial progress in international collaboration in leukemia research. On April 27-28, 2005, the 8th Meeting was held in Vienna, Austria, to continue the discussions about special common treatment elemen...

    journal_title：Leukemia

    pub_type：

    doi：10.1038/sj.leu.2404016

    authors： Gadner H,Masera G,Schrappe M,Eden T,Benoit Y,Harrison C,Nachman J,Pui CH

    更新日期：2006-01-01 00:00:00

  • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

    abstract：:Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.78

    authors： Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

    更新日期：2014-09-01 00:00:00

  • Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.

    abstract：:Monoclonal antibody (mAb) M195 is a mouse IgG2a reactive with a myelomonocytic differentiation antigen found on early myeloid cells and monocytes. The reactivity of M195 with fresh hematopoietic neoplasms in the blood or bone marrow from 227 patients at Memorial Hospital was determined by flow cytometry. M195 was posi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Scheinberg DA,Tanimoto M,McKenzie S,Strife A,Old LJ,Clarkson BD

    更新日期：1989-06-01 00:00:00

  • RT-PCR in acute promyelocytic leukemia: second workshop of the European Retinoic Group, Paris, France, 17-18 December 1994.

    abstract：:Reverse transcriptase-polymerase chain reaction is a recent technique in the diagnosis and assessment of minimal residual disease of acute promyelocytic leukemia, by amplification, of the different PML-RARalpha transcripts resulting from the t(15;17) translocation. The main issues addressed by the Second Workshop on P...

    journal_title：Leukemia

    pub_type：

    doi：

    authors：

    更新日期：1996-02-01 00:00:00

  • t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.

    abstract：:Structural rearrangements involving the short arm of chromosome 12 occur in 10% of cases of childhood acute lymphoid leukemia. The translocation t(12;17)(p13;q21), an uncommon 12p abnormality, was identified in five of 2620 cases (0.2%) successfully karyotyped by the Pediatric Oncology Group or St Jude Children's Rese...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Krance RA,Raimondi SC,Dubowy R,Estrada J,Borowitz M,Behm F,Land VJ,Pullen J,Carroll AJ

    更新日期：1992-04-01 00:00:00

  • Secondary chromosomal abnormalities in acute leukemias.

    abstract：:Secondary chromosomal aberrations reported in the literature were surveyed in acute myeloid or lymphoblastic leukemia (AML or ALL) with one of the following primary abnormalities: in AML, t(1;3), t(1;22), der(1;7), inv(3), t(3;5) +4, del(5q), t(6;9), -7, t(7;11), del(7q), +8, t(8;16), t(8;21), +9, t(9;11), del(9q), t(...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Johansson B,Mertens F,Mitelman F

    更新日期：1994-06-01 00:00:00

  • Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.

    abstract：:Natural killer (NK) cells are the first lymphocytes to recover after allogeneic stem cell transplantation (SCT) and can exert powerful graft-versus-leukemia (GVL) effects determining transplant outcome. Conditions governing NK cell alloreactivity and the role of NK recovery in sibling SCT are not well defined. NK cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404892

    authors： Savani BN,Mielke S,Adams S,Uribe M,Rezvani K,Yong AS,Zeilah J,Kurlander R,Srinivasan R,Childs R,Hensel N,Barrett AJ

    更新日期：2007-10-01 00:00:00

  • Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.

    abstract：:Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are scarce. The aim of this nationwide population-based study is to assess trends in primary therapy and relative survival (RS) during 1989-2017. We included 9,985 patients with cHL. Radiotherapy alone was virtually not appl...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0875-0

    authors： Driessen J,Visser O,Zijlstra JM,Lugtenburg PJ,Plattel WJ,Kersten MJ,Dinmohamed AG

    更新日期：2020-05-28 00:00:00

  • OCT1 and imatinib transport in CML: is it clinically relevant?

    abstract：:Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2015.170

    authors： Watkins DB,Hughes TP,White DL

    更新日期：2015-10-01 00:00:00

  • Chromatin structure and transcriptional regulation of the stem cell leukaemia (SCL) gene in mast cells.

    abstract：:The stem cell leukaemia (SCL) gene is a member of the basic helix-loop-helix family of transcription factors and is essential for the development of all haematopoietic lineages. SCL is expressed in pluripotent haematopoietic stem cells and also following commitment to the erythroid, mast and megakaryocytic lineages. T...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401420

    authors： Fordham JL,Göttgens B,McLaughlin F,Green AR

    更新日期：1999-05-01 00:00:00

  • Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

    abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the effic...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.111

    authors： Giles FJ,O'Dwyer M,Swords R

    更新日期：2009-10-01 00:00:00

  • 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.

    abstract：:14-3-3 proteins are a family of master regulators of intracellular signaling, yet their impact on proteasome function is unknown. We demonstrate that 14-3-3ζ binds the 11S proteasome activator, limiting proteasome assembly and cellular capacity for protein degradation. To define the functional impact of 14-3-3ζ protea...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.288

    authors： Gu Y,Xu K,Torre C,Samur M,Barwick BG,Rupji M,Arora J,Neri P,Kaufman J,Nooka A,Bernal-Mizrachi L,Vertino P,Sun SY,Chen J,Munshi N,Fu H,Kowalski J,Boise LH,Lonial S

    更新日期：2018-03-01 00:00:00

  • Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

    abstract：:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.46

    authors： Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

    更新日期：2017-10-01 00:00:00

  • Relation between cell cycle stage and the activity of DNA-synthesizing enzymes in cultured human lymphoblasts: investigations on cells separated according to DNA content by way of a cell sorter.

    abstract：:Exponentially growing human lymphoblasts (culture LS-2) were separated by cell sorting (FACS II, Becton Dickinson) according to their deoxyribonucleic acid (DNA) content, designating them at particular phases of the cell cycle. Prior to cell sorting the DNA has been fluorochrome-labeled with the Hoechst stain H 33342....

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Pelka-Fleischer R,Fleischer W,Wilmanns W,Sauer H,Schalhorn A

    更新日期：1989-05-01 00:00:00

  • Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

    abstract：:In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 mul...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,评审

    doi：10.1038/sj.leu.2403202

    authors： van Dongen JJ,Langerak AW,Brüggemann M,Evans PA,Hummel M,Lavender FL,Delabesse E,Davi F,Schuuring E,García-Sanz R,van Krieken JH,Droese J,González D,Bastard C,White HE,Spaargaren M,González M,Parreira A,Smith JL,Mor

    更新日期：2003-12-01 00:00:00

  • Constitutive expression of GM-CSF mRNA by CML blast cells is correlated with endogenous megakaryocytic colony formation.

    abstract：:Purified blast cells from peripheral blood of 12 patients, with chronic myelogenous leukemia (CML) in chronic phase, were analyzed for the constitutive expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) transcript. Seven out 12 patients exhibited the specific 1.0 kb GM-CSF mRNA. Six from these...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Lajmanovich A,Berthier R,Schweitzer A,Leger J,Hollard D

    更新日期：1993-08-01 00:00:00

  • Is the mdr 1 gene relevant in chronic lymphocytic leukemia?

    abstract：:Chronic lymphocytic leukemia (CLL) is a progressive disease in which chemotherapy may result in temporary suppression of the peripheral blood lymphocyte count, but cure is not usually possible. Drug resistance mechanisms and the multidrug resistant (MDR) phenotype may be relevant to the therapeutic response. We have s...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Holmes JA,Jacobs A,Carter G,Whittaker JA,Bentley DP,Padua RA

    更新日期：1990-03-01 00:00:00

  • Expression of the LH2 gene in chronic myeloid leukaemia cells.

    abstract：:The LH2 gene encodes a putative transcription factor containing two N-terminal LIM and one C-terminal HOX domains. The LH2 locus was mapped to 9q33-34.1, centromeric to the ABL gene. In a recent report, it was suggested that high levels of LH2 expression are consistently observed in chronic myeloid leukemia (CML) pati...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Al-Jehani F,Hochhaus A,Spencer A,Goldman JM,Melo JV

    更新日期：1996-07-01 00:00:00

  • Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.

    abstract：:In this study, the abilities of constitutive and conditional forms of the three Raf kinases to abrogate the cytokine dependency of FDC-P1 cells were examined. The constitutively active forms (delta) of all three Raf kinases were fused to the hormone-binding domain of the estrogen receptor (ER), rendering their activit...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401720

    authors： Hoyle PE,Moye PW,Steelman LS,Blalock WL,Franklin RA,Pearce M,Cherwinski H,Bosch E,McMahon M,McCubrey JA

    更新日期：2000-04-01 00:00:00

  • Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.

    abstract：:Molecular cloning of immunoglobulin heavy chain (IGH) translocation breakpoints identifies genes of biological importance in the development of normal and malignant B cells. Long-distance inverse PCR (LDI-PCR) was first applied to amplification of IGH gene translocations targeted to the joining (IGHJ) regions. We repo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403500

    authors： Sonoki T,Willis TG,Oscier DG,Karran EL,Siebert R,Dyer MJ

    更新日期：2004-12-01 00:00:00

  • The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.

    abstract：:Improved survival of patients with acute lymphoblastic leukemia (ALL) has emerged from identifying new prognostic markers; however, 20% of children still suffer recurrence. Previously, the altered expression of Fat1 cadherin has been implicated in a number of solid tumors. In this report, in vitro analysis shows that ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.319

    authors： de Bock CE,Ardjmand A,Molloy TJ,Bone SM,Johnstone D,Campbell DM,Shipman KL,Yeadon TM,Holst J,Spanevello MD,Nelmes G,Catchpoole DR,Lincz LF,Boyd AW,Burns GF,Thorne RF

    更新日期：2012-05-01 00:00:00

  • Harmonization of molecular monitoring of CML therapy in Europe.

    abstract：:The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.168

    authors： Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

    更新日期：2009-11-01 00:00:00

  • Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas.

    abstract：:Several studies using sensitive in situ hybridization techniques show that, in non-immunocompromised patients, Epstein-Barr virus (EBV) is more frequently detected in lymphomas expressing T cell markers than in B cell lymphomas. Among lymphomas expressing T cell markers, the presence of EBV is highly related to the si...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Kanavaros P,Briere J,Emile JF,Gaulard P

    更新日期：1996-06-01 00:00:00

  • Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.

    abstract：:Lack of apoptosis has been linked to prolonged survival of malignant B cells expressing bcl-2. The aim of the present study was to analyze the amount of bcl-2 protein expressed along normal human B-cell maturation and to establish the frequency of aberrant bcl-2 expression in B-cell malignancies. In normal bone marrow...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403231

    authors： Menendez P,Vargas A,Bueno C,Barrena S,Almeida J,De Santiago M,López A,Roa S,San Miguel JF,Orfao A

    更新日期：2004-03-01 00:00:00

  • Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.

    abstract：:Currently available data regarding the substrate specificity of the multi-drug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-associated protein (MRP1) for idarubicin are inconclusive. A multiparameter flow cytometry method was developed which allows simultaneous quantitative measurement of total cellular fl...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401496

    authors： Smeets ME,Raymakers RA,Vierwinden G,Pennings AH,Boezeman J,Minderman H,de Witte TM

    更新日期：1999-09-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract：:Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.leu.2405087

    authors： San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期：2008-04-01 00:00:00